Allarity Therapeutics (ALLR) Net Equity Issued and Repurchased (2020 - 2025)

Allarity Therapeutics (ALLR) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $11.1 million in Q1 2025.

• Quarterly Net Equity Issued and Repurchased rose 27757.5% year-over-year to $11.1 million in Q1 2025, while the trailing twelve-month figure through Dec 2025 was $11.1 million (down 70.15% YoY) and the FY2025 annual result came in at $11.1 million, down 70.17% from the prior year.
• Net Equity Issued and Repurchased grew to $11.1 million in Q1 2025, from $4.2 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $27.6 million in Q2 2024 to a low of $40000.0 in Q1 2024.
• A 4-year average of $9.5 million and a median of $6.4 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2024 — Net Equity Issued and Repurchased soared 268.65% — and 2025, when it jumped 27757.5%.
• Tracing ALLR's Net Equity Issued and Repurchased over 4 years: stood at $17.3 million in 2021, then sank by 56.52% to $7.5 million in 2023, then sank by 43.53% to $4.2 million in 2024, then jumped by 163.12% to $11.1 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $11.1 million (Q1 2025), $4.2 million (Q4 2024), and $5.4 million (Q3 2024), per Business Quant data.